Suchergebnisse - "Chung, David J."

The Simplified Comorbidity Index predicts non‐relapse mortality in reduced‐intensity conditioning allogeneic haematopoietic cell transplantation von Elias, Shlomo, Brown, Samantha, Devlin, Sean M., Barker, Juliet N., Cho, Christina, Chung, David J., Dahi, Parastoo B., Giralt, Sergio, Gyurkocza, Boglarka, Jakubowski, Ann A., Lahoud, Oscar B., Landau, Heather, Lin, Richard J., Papadopoulos, Esperanza B., Politikos, Ioannis, Ponce, Doris M., Scordo, Michael, Shaffer, Brian C., Shah, Gunjan L., Tamari, Roni, Young, James W., Perales, Miguel‐Angel, Shouval, Roni

“… Comorbidity assessment before allogeneic haematopoietic cell transplantation (allo‐HCT) is essential for estimating non‐relapse mortality (NRM) risk. We …”
Volltext

Evaluating serum free light chain ratio as a biomarker in multiple myeloma von Akhlaghi, Theresia, Maclachlan, Kylee, Korde, Neha, Mailankody, Sham, Lesokhin, Alexander, Hassoun, Hani, Lu, Sydney X, Patel, Dhwani, Shah, Urvi, Tan, Carlyn, Derkach, Andriy, Lahoud, Oscar, Landau, Heather J, Shah, Gunjan L., Scordo, Michael, Chung, David J, Giralt, Sergio A, Usmani, Saad Z, Landgren, Ola, Hultcrantz, Malin

“… Not available.Not available …”
Volltext

Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma von Tan, Carlyn Rose, Derkach, Andriy, Nemirovsky, David, Ciardiello, Amanda, Diamond, Benjamin, Hultcrantz, Malin, Hassoun, Hani, Mailankody, Sham, Shah, Urvi, Maclachlan, Kylee, Patel, Dhwani, Lahoud, Oscar B., Landau, Heather J., Chung, David J., Shah, Gunjan L., Scordo, Michael, Giralt, Sergio A., Lesokhin, Alexander, Usmani, Saad Z., Landgren, Ola, Korde, Neha

“… Lenalidomide and dexamethasone with bortezomib (VRd) or carfilzomib (KRd) are commonly used induction regimens in the U.S. This single-center, retrospective …”
Volltext

Disease- and Therapy-Specific Impact on Humoral Immune Responses to COVID-19 Vaccination in Hematologic Malignancies von Chung, David J, Shah, Gunjan L, Devlin, Sean M, Ramanathan, Lakshmi V, Doddi, Sital, Pessin, Melissa S, Hoover, Elizabeth, Marcello, LeeAnn T, Young, Jennifer C, Boutemine, Sawsan R, Serrano, Edith, Sharan, Saumya, Momotaj, Saddia, Margetich, Lauren, Bravo, Christina D, Papanicolaou, Genovefa A, Kamboj, Mini, Mato, Anthony R, Roeker, Lindsey E, Hultcrantz, Malin, Mailankody, Sham, Lesokhin, Alexander M, Vardhana, Santosha A, Knorr, David A

“… Coronavirus disease-19 (COVID-19) vaccine response data for patients with hematologic malignancy, who carry high risk for severe COVID-19 illness, are …”
Weitere Angaben

Acupuncture for reduction of symptom burden in multiple myeloma patients undergoing autologous hematopoietic stem cell transplantation: a randomized sham-controlled trial von Deng, Gary, Giralt, Sergio, Chung, David J., Landau, Heather, Siman, Jonathan, Search, Benjamin, Coleton, Marci, Vertosick, Emily, Shapiro, Nathan, Chien, Christine, Wang, Xin S., Cassileth, Barrie, Mao, Jun J.

“… Purpose Hematopoietic stem cell transplantation (HCT) is potentially curative for a number of hematologic malignancies, but is associated with high symptom …”
Volltext

Comparison of infectious complications with BCMA-directed therapies in multiple myeloma von Nath, Karthik, Shekarkhand, Tala, Nemirovsky, David, Derkach, Andriy, Costa, Bruno Almeida, Nishimura, Noriko, Farzana, Tasmin, Rueda, Colin, Chung, David J., Landau, Heather J., Lahoud, Oscar B., Scordo, Michael, Shah, Gunjan L., Hassoun, Hani, Maclachlan, Kylee, Korde, Neha, Shah, Urvi A., Tan, Carlyn Rose, Hultcrantz, Malin, Giralt, Sergio A., Usmani, Saad Z., Shahid, Zainab, Mailankody, Sham, Lesokhin, Alexander M.

“… B-cell-maturation-antigen (BCMA)-directed therapies are highly active for multiple myeloma, but infections are emerging as a major challenge. In this …”
Volltext

Prognostic impact of corticosteroid and tocilizumab use following chimeric antigen receptor T-cell therapy for multiple myeloma von Costa, Bruno Almeida, Flynn, Jessica, Nishimura, Noriko, Devlin, Sean M., Farzana, Tasmin, Rajeeve, Sridevi, Chung, David J., Landau, Heather J., Lahoud, Oscar B., Scordo, Michael, Shah, Gunjan L., Hassoun, Hani, Maclachlan, Kylee, Hultcrantz, Malin, Korde, Neha, Lesokhin, Alexander M., Shah, Urvi A., Tan, Carlyn R., Giralt, Sergio A., Usmani, Saad Z., Nath, Karthik, Mailankody, Sham

“… Despite being the mainstay of management for cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), there is …”
Volltext

Assessment of renal outcome following therapy in monoclonal immunoglobulin deposition disease: Emphasizing the need for a consensus approach von Pianko, Matthew J., Tiutan, Timothy, Derkach, Andriy, Flynn, Jessica, Salvatore, Steven P., Jaffer‐Sathick, Insara, Rossi, Adriana C., Lahoud, Oscar, Hultcrantz, Malin, Shah, Urvi A., Maclachlan, Kylee, Chung, David J., Shah, Gunjan L., Landau, Heather J., Korde, Neha, Mailankody, Sham, Lesokhin, Alexander M., Tan, Carlyn, Scordo, Michael, Jaimes, Edgar A., Giralt, Sergio A., Usmani, Saad, Hassoun, Hani

“… Monoclonal immunoglobulin deposition disease (MIDD), often associated with plasma cell dyscrasias, predominantly affects the kidneys. In this disease, …”
Volltext

Predictive biomarkers and practical considerations in the management of carfilzomib-associated cardiotoxicity von Lendvai, Nikoletta, Tsakos, Ioanna, Devlin, Sean M., Schaffer, Wendy L., Hassoun, Hani, Lesokhin, Alexander M., Landau, Heather, Korde, Neha, Mailankody, Sham, Smith, Eric, Chung, David J., Koehne, Guenther, Shah, Gunjan L., Alexander, Aeri, Patel, Minal, Ballagi, Andrea, Grundberg, Ida, Giralt, Sergio A., Landgren, Ola

Volltext

Colesevelam for lenalidomide associated diarrhea in patients with multiple myeloma von Hultcrantz, Malin, Hassoun, Hani, Korde, Neha, MacLachlan, Kylee, Mailankody, Sham, Patel, Dhwani, Shah, Urvi A., Tan, Carlyn Rose, Chung, David J., Lahoud, Oscar B., Landau, Heather J., Scordo, Michael, Shah, Gunjan L., Giralt, Sergio A., Pianko, Matthew J., Burge, Miranda, Barnett, Kelly, Salcedo, Meghan, Caple, Julia, Tran, Linh, Blaslov, Jenna, Shekarkhand, Tala, Hamid, Selena, Nemirovsky, David, Derkach, Andriy, Arisa, Oluwatobi, Peer, Cody J., Figg, William D., Usmani, Saad Z., Landgren, Ola, Lesokhin, Alexander M.

Volltext

Langerhans-type dendritic cells electroporated with TRP-2 mRNA stimulate cellular immunity against melanoma: Results of a phase I vaccine trial von Chung, David J., Carvajal, Richard D., Postow, Michael A., Sharma, Sneh, Pronschinske, Katherine B., Shyer, Justin A., Singh-Kandah, Shahnaz, Dickson, Mark A., D'Angelo, Sandra P., Wolchok, Jedd D., Young, James W.

“… Purpose: We conducted a phase I vaccine trial to determine safety, toxicity, and immunogenicity of autologous Langerhans-type dendritic cells (LCs), …”
Volltext

Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells von Chung, David J, Rossi, Marco, Romano, Emanuela, Ghith, Jennifer, Yuan, Jianda, Munn, David H, Young, James W

“… A comprehensive understanding of the complex, autologous cellular interactions and regulatory mechanisms that occur during normal dendritic cell …”
Weitere Angaben

Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies von Stuver, Robert, Shah, Gunjan L, Korde, Neha S, Roeker, Lindsey E, Mato, Anthony R, Batlevi, Connie L, Chung, David J, Doddi, Sital, Falchi, Lorenzo, Gyurkocza, Boglarka, Hamilton, Audrey, Lin, Ya-Hui, Jakubowski, Ann A, Joffe, Erel, Landau, Heather L, Lin, Richard J, Mailankody, Sham, Palomba, M Lia, Park, Jae H, Perales, Miguel-Angel, Ponce, Doris M, Ramanathan, Lakshmi V, Salles, Gilles A, Scordo, Michael, Seo, Susan K, Shah, Urvi A, Stein, Eytan M, Straus, David, Usmani, Saad Z, Young, James W, Zelenetz, Andrew D, Noy, Ariela, Vardhana, Santosha A

Weitere Angaben

Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myeloma von Firestone, Ross S, Socci, Nicholas D, Shekarkhand, Tala, Zhu, Menglei, Qin, Wei Ge, Hultcrantz, Malin, Mailankody, Sham, Tan, Carlyn Rose, Korde, Neha, Lesokhin, Alexander M, Hassoun, Hani, Shah, Urvi, Maclachlan, Kylee H, Rajeeve, Sridevi, Landau, Heather J, Scordo, Michael, Shah, Gunjan L, Lahoud, Oscar B, Giralt, Sergio, Murata, Kazunori, Usmani, Saad Z, Chung, David J

“… B-cell maturation antigen (BCMA)-targeting therapeutics have dramatically improved outcomes in relapsed/refractory multiple myeloma (RRMM). However, whether …”
Weitere Angaben

Tracking the evolution of therapy-related myeloid neoplasms using chemotherapy signatures von Diamond, Benjamin, Ziccheddu, Bachisio, Maclachlan, Kylee, Taylor, Justin, Boyle, Eileen, Ossa, Juan Arango, Jahn, Jacob, Affer, Maurizio, Totiger, Tulasigeri M, Coffey, David, Chandhok, Namrata, Watts, Justin, Cimmino, Luisa, Lu, Sydney X, Bolli, Niccolò, Bolton, Kelly, Landau, Heather, Park, Jae H, Ganesh, Karuna, McPherson, Andrew, Sekeres, Mikkael A, Lesokhin, Alexander, Chung, David J, Zhang, Yanming, Ho, Caleb, Roshal, Mikhail, Tyner, Jeffrey, Nimer, Stephen, Papaemmanuil, Elli, Usmani, Saad, Morgan, Gareth, Landgren, Ola, Maura, Francesco

“… Patients treated with cytotoxic therapies, including autologous stem cell transplantation, are at risk for developing therapy-related myeloid neoplasms (tMN) …”
Weitere Angaben

Regulation of the hematopoietic stem cell pool by C-Kit-associated trogocytosis von Gao, Xin, Carpenter, Randall S, Boulais, Philip E, Zhang, Dachuan, Marlein, Christopher R, Li, Huihui, Smith, Matthew, Chung, David J, Maryanovich, Maria, Will, Britta, Steidl, Ulrich, Frenette, Paul S

“… Hematopoietic stem cells (HSCs) are routinely mobilized from the bone marrow (BM) to the blood circulation for clinical transplantation. However, the precise …”
Weitere Angaben

Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401 von Chung, David J, Shah, Nina, Wu, Juan, Logan, Brent, Bisharat, Lina, Callander, Natalie, Cheloni, Giulia, Anderson, Kenneth, Chodon, Thinle, Dhakal, Binod, Devine, Steve, Somaiya Dutt, Poorvi, Efebera, Yvonne, Geller, Nancy, Ghiasuddin, Haider, Hematti, Peiman, Holmberg, Leona, Howard, Alan, Johnson, Bryon, Karagkouni, Dimitra, Lazarus, Hillard M, Malek, Ehsan, McCarthy, Philip, McKenna, David, Mendizabal, Adam, Nooka, Ajay, Munshi, Nikhil, O'Donnell, Lynn, Rapoport, Aaron P, Reese, Jane, Rosenblatt, Jacalyn, Soiffer, Robert, Stroopinsky, Dina, Uhl, Lynne, Vlachos, Ioannis S, Waller, Edmund K, Young, James W, Pasquini, Marcelo C, Avigan, David

“… Vaccination with dendritic cell (DC)/multiple myeloma (MM) fusions has been shown to induce the expansion of circulating multiple myeloma-reactive lymphocytes …”
Weitere Angaben

Sustained Minimal Residual Disease Negativity in Multiple Myeloma is Associated with Stool Butyrate and Healthier Plant-Based Diets von Shah, Urvi A, Maclachlan, Kylee H, Derkach, Andriy, Salcedo, Meghan, Barnett, Kelly, Caple, Julia, Blaslov, Jenna, Tran, Linh, Ciardiello, Amanda, Burge, Miranda, Shekarkhand, Tala, Adintori, Peter, Cross, Justin, Pianko, Matthew J, Hosszu, Kinga, McAvoy, Devin, Mailankody, Sham, Korde, Neha, Hultcrantz, Malin, Hassoun, Hani, Tan, Carlyn R, Lu, Sydney X, Patel, Dhwani, Diamond, Benjamin, Shah, Gunjan, Scordo, Michael, Lahoud, Oscar, Chung, David J, Landau, Heather, Usmani, Saad Z, Giralt, Sergio, Taur, Ying, Landgren, C Ola, Block, Gladys, Block, Torin, Peled, Jonathan U, van den Brink, Marcel R M, Lesokhin, Alexander M

“… Sustained minimal residual disease (MRD) negativity is associated with long-term survival in multiple myeloma. The gut microbiome is affected by diet, and in …”
Weitere Angaben

Phase I Trial of MCARH109, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma: An Updated Analysis von Jurgens, Eric M, Firestone, Ross S, Chaudhari, Jagrutiben, Hosszu, Kinga, Devlin, Sean M, Shah, Urvi A, Landa, Jonathan, McAvoy, Devin P, Lesokhin, Alexander M, Korde, Neha, Hassoun, Hani, Tan, Carlyn R, Hultcrantz, Malin, Shah, Gunjan L, Landau, Heather J, Chung, David J, Scordo, Michael, Eren, Ozgur Can, Dogan, Ahmet, Giralt, Sergio A, Park, Jae H, Rivière, Isabelle, Brentjens, Renier J, Smith, Eric L, Wang, Xiuyan, Usmani, Saad Z, Mailankody, Sham

“… MCARH109 is a first-in-class G protein-coupled receptor, class C, group 5, member D (GPRC5D)-targeted chimeric antigen receptor (CAR) T-cell therapy for …”
Weitere Angaben

T-cell Exhaustion in Multiple Myeloma Relapse after Autotransplant: Optimal Timing of Immunotherapy von Chung, David J, Pronschinske, Katherine B, Shyer, Justin A, Sharma, Sneh, Leung, Samantha, Curran, Shane A, Lesokhin, Alexander M, Devlin, Sean M, Giralt, Sergio A, Young, James W

“… Multiple myeloma is the most common indication for high-dose chemotherapy and autologous stem cell transplantation (ASCT), and lenalidomide maintenance after …”
Weitere Angaben